Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Neurology

How to Evaluate a Neurologist's SREAT and AE Expertise

At a Glance

An experienced neurologist evaluates SREAT as a diagnosis of exclusion, does not rely on thyroid antibodies alone, and matches serum or spinal-fluid antibody results to symptoms. They should also offer a clear treatment, safety-monitoring, EEG, and cognitive follow-up plan.

In this answer

3 sections

01

Understanding SREAT as a Diagnosis of Exclusion

02

The Approach to Treatment and Safety

03

Objective Cognitive and EEG Monitoring

When dealing with a rare and complex condition like Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT)—often called Hashimoto’s encephalopathy—or autoimmune encephalitis (AE), finding the right specialist is critical. Because general neurologists may only see a few cases of autoimmune brain disease, you might seek out a neuroimmunologist or an epilepsy specialist. Rather than looking for a doctor who orders every possible test, look for a clinician who embraces a thoughtful, individualized approach, clearly explains the uncertainty surrounding these conditions, and has a concrete plan for evaluating and treating you [1].

Evaluating your doctor’s familiarity with clinical diagnostic guidelines, their approach to immune therapies, and their use of cognitive and brain-wave monitoring can help you ensure you are receiving expert care.

Understanding SREAT as a Diagnosis of Exclusion

A knowledgeable neurologist will explain that SREAT does not have a single definitive biomarker and remains a controversial diagnosis [2]. They will view it as a “diagnosis of exclusion,” meaning they must rule out other causes before considering it [3].

  • The Graus 2016 Criteria: These are standard clinical guidelines used to evaluate suspected autoimmune encephalitis [4]. While they are not diagnostic criteria for SREAT itself, specialists use them to systematically identify defined antibody syndromes and distinguish them from conditions that mimic AE [4][5].
  • Looking Beyond Thyroid Antibodies: Having elevated thyroid antibodies does not automatically mean your brain symptoms are caused by SREAT; many healthy people have these antibodies [1][3]. A specialist will thoroughly investigate other potential causes, such as infections, medication or toxin effects, metabolic imbalances, non-autoimmune seizures, neurodegenerative disorders, and primary psychiatric illnesses [2][1][6].
  • Individualized Antibody Testing: To check for specific AE syndromes, your doctor may order neural antibody panels on your blood (serum), your spinal fluid (CSF), or both [7]. An experienced doctor knows that the choice of tests depends on your symptoms and that a negative panel does not entirely rule out AE, nor does a positive panel automatically confirm it without matching clinical signs [5][8][9].

The Approach to Treatment and Safety

Because the evidence base for SREAT specifically is limited and largely based on case studies, treatments are often adapted from broader AE protocols [10][11]. A specialist will have a clear, step-by-step plan.

  • First-Line Therapies: High-dose steroids (corticosteroids) are the traditional starting point [11]. In moderate-to-severe AE presentations, specialists may also use them alongside Intravenous Immunoglobulin (IVIG) or therapeutic plasma exchange (PLEX) [12][13].
  • Second-Line and Maintenance Therapies: If you do not respond well to initial treatments or if you relapse, your doctor may discuss escalating therapy. This might involve rituximab or, more rarely, cyclophosphamide for refractory disease [12][14]. For long-term maintenance or to help you safely taper off steroids (steroid-sparing), medications like azathioprine or mycophenolate mofetil might be considered [15][16].
  • Comprehensive Safety Monitoring: Immune-suppressing medications require strict individualized monitoring. Your doctor should check blood counts, liver and kidney function, natural immunoglobulin levels, and screen for infections or vaccine needs [17][18][19]. If you are on prolonged steroids, they should monitor your blood pressure, glucose, bone health, mood, and eye pressure [20]. Safety Note: Never abruptly stop taking corticosteroids without medical supervision, as rapid withdrawal can be highly dangerous.

Objective Cognitive and EEG Monitoring

Recovery from AE or SREAT can be gradual and uneven. Fatigue, memory issues, and mood changes may persist even after brain inflammation is controlled [21]. A specialist will use objective tools when appropriate to monitor your progress over time.

  • Targeted EEG Use: An EEG (electroencephalogram) measures brain waves. While abnormal electrical activity is frequently seen in these conditions, a normal EEG does not rule out AE, and an abnormal EEG does not confirm SREAT [10]. Specialists may order prolonged continuous or ambulatory EEG if you have persistent unexplained confusion, unusual spells, or suspected non-convulsive seizures (seizures that happen inside the brain without physical shaking) [22][23][24].
  • Cognitive Testing: Your care team may use brief screening tools like the MoCA (Montreal Cognitive Assessment) to track changes in attention and memory [25]. However, these are just screens and scores can be heavily affected by fatigue, mood, and education level. For a detailed evaluation, formal neuropsychological testing may be recommended [26].
  • Quality of Life and Function: Because clinical testing doesn’t capture everything, experts will ask about—or use formal questionnaires for—your mood, sleep, daily functioning, and caregiver observations [27][28].

Urgent Care Warning: Seek immediate medical attention if you experience new or prolonged seizures, rapidly worsening confusion, severe psychiatric symptoms, inability to maintain hydration, or signs of serious infection, rather than waiting for a specialist appointment.

Common questions in this guide

What should an expert neurologist explain about SREAT?
An experienced neurologist should explain that SREAT has no single definitive biomarker and is usually considered a diagnosis of exclusion. They should review infections, medication or toxin effects, metabolic problems, seizures, neurodegenerative disease, and psychiatric conditions rather than relying on thyroid antibody levels alone.
Do high thyroid antibodies prove that I have SREAT?
No. Thyroid antibodies can be found in people who do not have SREAT, so a high level does not by itself show that brain symptoms are caused by the condition. The diagnosis depends on the clinical picture and careful evaluation for other causes.
How are autoimmune encephalitis tests chosen?
A specialist may use the Graus 2016 clinical approach and order neural antibody testing in blood, spinal fluid, or both, based on your symptoms. A negative panel does not completely exclude autoimmune encephalitis, and a positive result must fit the clinical picture before it is used to guide treatment.
What treatments might a neurologist consider for SREAT or autoimmune encephalitis?
High-dose corticosteroids are often used first, while IVIG or plasma exchange may be added for moderate-to-severe presentations. If symptoms persist or return, a specialist may discuss rituximab or other immune-suppressing medicines, and may consider azathioprine or mycophenolate to reduce long-term steroid use.
How should treatment safety be monitored?
Monitoring may include blood counts, liver and kidney tests, immunoglobulin levels, infection screening, and review of vaccine needs. During prolonged steroid treatment, clinicians may also check blood pressure, glucose, bone health, mood, and eye pressure; corticosteroids should never be stopped suddenly without medical supervision.
When are EEG and cognitive tests useful in recovery?
Prolonged or ambulatory EEG may be useful for ongoing confusion, unusual spells, or suspected seizures that occur without visible shaking, but a normal EEG does not rule out autoimmune encephalitis. Brief cognitive screens such as the MoCA can track attention and memory, while formal neuropsychological testing gives a more detailed assessment when needed.
When should someone with possible autoimmune encephalitis seek urgent care?
Seek immediate medical attention for new or prolonged seizures, rapidly worsening confusion, severe psychiatric symptoms, inability to stay hydrated, or signs of a serious infection. Do not wait for a routine specialist appointment when these symptoms occur.

Related questions

Are Seizures, Tremors, and Ataxia Common in SREAT? Can SREAT Cause Only Psychiatric Symptoms Like Psychosis? Do Thyroid Antibodies Cause Brain Inflammation in SREAT? Can Thyroid Antibody Levels Predict SREAT Relapses? How Is SREAT Differentiated From Dementia and CJD?
Show more
Is a Normal Brain MRI Common in Hashimoto's Encephalopathy? What Are SREAT Clinical Subtypes and Onset Patterns? Can Delayed SREAT Cause Long-Term Cognitive Effects? What Are SREAT Second-Line Treatments After Steroids Fail? SREAT Relapse vs. Steroid Withdrawal: Warning Signs What Do CSF and Spinal Tap Results Show for SREAT? How Rare Is SREAT? Incidence, Prevalence, and Causes How long does steroid treatment for SREAT usually last? What Specialists Manage Hashimoto's Encephalopathy? Why Is TSH Usually Normal in Hashimoto's Encephalopathy?

Get notified when new evidence is published on Steroid-responsive encephalopathy associated with autoimmune thyroiditis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (28)
  1. 1

    Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis.

    Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, et al.

    Brain communications 2021; (3(2)):fcaa233 doi:10.1093/braincomms/fcaa233.

    PMID: 34061124
  2. 2

    Hashimoto's Encephalopathy: Case Series and Literature Review.

    Chaudhuri J, Mukherjee A, Chakravarty A

    Current neurology and neuroscience reports 2023; (23(4)):167-175 doi:10.1007/s11910-023-01255-5.

    PMID: 36853554
  3. 3

    Hashimoto encephalopathy in the 21st century.

    Mattozzi S, Sabater L, Escudero D, et al.

    Neurology 2020; (94(2)):e217-e224 doi:10.1212/WNL.0000000000008785.

    PMID: 31882532
  4. 4

    A clinical approach to diagnosis of autoimmune encephalitis.

    Graus F, Titulaer MJ, Balu R, et al.

    The Lancet. Neurology 2016; (15(4)):391-404.

    PMID: 26906964
  5. 5

    Mimics of Autoimmune Encephalitis: Validation of the 2016 Clinical Autoimmune Encephalitis Criteria.

    Van Steenhoven RW, de Vries JM, Bruijstens AL, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2023; (10(6)) doi:10.1212/NXI.0000000000200148.

    PMID: 37582614
  6. 6

    Steroid-responsive encephalopathy in autoimmune thyroiditis (SREAT) as a differential diagnosis of Creutzfeldt-Jakob disease.

    Osmanlıoğlu Ş, Zerr I

    Neurologia i neurochirurgia polska 2023; (57(2)):198-205 doi:10.5603/PJNNS.a2023.0005.

    PMID: 36727548
  7. 7

    Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease.

    Dalmau J, Graus F

    The Lancet. Neurology 2023; (22(6)):529-540 doi:10.1016/S1474-4422(23)00083-2.

    PMID: 37210100
  8. 8

    Autoimmune Encephalitis Misdiagnosis in Adults.

    Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al.

    JAMA neurology 2023; (80(1)):30-39 doi:10.1001/jamaneurol.2022.4251.

    PMID: 36441519
  9. 9

    Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis.

    Ruiz-García R, Muñoz-Sánchez G, Naranjo L, et al.

    Frontiers in immunology 2021; (12()):691536 doi:10.3389/fimmu.2021.691536.

    PMID: 34267758
  10. 10

    Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature.

    Laurent C, Capron J, Quillerou B, et al.

    Autoimmunity reviews 2016; (15(12)):1129-1133 doi:10.1016/j.autrev.2016.09.008.

    PMID: 27639840
  11. 11

    A Case Series of Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis (SREAT) With Atypical Thyroid Lab and Imaging Findings.

    Johnson MS, Petrovsky M, Rinehart Mimbella R, et al.

    Case reports in neurological medicine 2026; (2026()):8314930 doi:10.1155/crnm/8314930.

    PMID: 42131223
  12. 12

    Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.

    Abboud H, Probasco JC, Irani S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2021; (92(7)):757-768 doi:10.1136/jnnp-2020-325300.

    PMID: 33649022
  13. 13

    Clinical efficacy of plasma exchange in patients with autoimmune encephalitis.

    Zhang Y, Huang HJ, Chen WB, et al.

    Annals of clinical and translational neurology 2021; (8(4)):763-773 doi:10.1002/acn3.51313.

    PMID: 33609012
  14. 14

    Antibody Therapies in Autoimmune Encephalitis.

    Smets I, Titulaer MJ

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):823-831 doi:10.1007/s13311-021-01178-4.

    PMID: 35060089
  15. 15

    [A suspected case of Hashimoto encephalopathy with frequent relapses despite multiple courses of immunotherapy].

    Harada S, Inatomi Y, Nakajima M, Yonehara T

    Rinsho shinkeigaku = Clinical neurology 2020; (60(3)):200-205 doi:10.5692/clinicalneurol.cn-001361.

    PMID: 32101843
  16. 16

    Immunotherapies on autoimmune encephalitis.

    Lemmens CMC, Van Sonderen A, Titulaer MJ

    Handbook of clinical neurology 2026; (214()):269-289 doi:10.1016/B978-0-323-90887-0.00004-3.

    PMID: 41526139
  17. 17

    Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.

    Hill M, Iro M, Sadarangani M, et al.

    BMJ open 2023; (13(11)):e072134 doi:10.1136/bmjopen-2023-072134.

    PMID: 37945292
  18. 18

    Comparison of intravenous immunoglobulin and plasma exchange in hospital-acquired infections of autoimmune encephalitis in a tertiary care center.

    Surawattanawong T, Hiransuthikul A, Katasrila P, et al.

    Asian biomedicine : research, reviews and news 2025; (19(3)):147-153 doi:10.2478/abm-2025-0018.

    PMID: 40735664
  19. 19

    Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis.

    Nepal G, Shing YK, Yadav JK, et al.

    Acta neurologica Scandinavica 2020; (142(5)):449-459 doi:10.1111/ane.13291.

    PMID: 32484900
  20. 20

    Efficacy and safety of different oral prednisone tapering courses in adult anti-NMDAR encephalitis: A multicenter prospective cohort study.

    Cai L, Li G, Abdulaziz AT, et al.

    Epilepsia 2024; (65(11)):3199-3215 doi:10.1111/epi.18107.

    PMID: 39324872
  21. 21

    Outcome and Sequelae of Autoimmune Encephalitis.

    Kvam KA, Stahl JP, Chow FC, et al.

    Journal of clinical neurology (Seoul, Korea) 2024; (20(1)):3-22 doi:10.3988/jcn.2023.0242.

    PMID: 38179628
  22. 22

    Autoimmune encephalitis as an increasingly recognised cause of non-convulsive status epilepticus: A retrospective, multicentre evaluation of patient characteristics and electroencephalography (EEG) results.

    Mitchell JW, Valdoleiros SR, Jefferson S, et al.

    Seizure 2020; (80()):153-156 doi:10.1016/j.seizure.2020.06.020.

    PMID: 32574837
  23. 23

    Continuous EEG Findings in Autoimmune Encephalitis.

    Moise AM, Karakis I, Herlopian A, et al.

    Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 2021; (38(2)):124-129 doi:10.1097/WNP.0000000000000654.

    PMID: 31800465
  24. 24

    [Initial Management of Status Epilepticus].

    Inaji M, Maehara T

    No shinkei geka. Neurological surgery 2023; (51(6)):1069-1077 doi:10.11477/mf.1436204853.

    PMID: 38011881
  25. 25

    Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations.

    Dutra LA, Silva PVC, Ferreira JHF, et al.

    Arquivos de neuro-psiquiatria 2024; (82(7)):1-15 doi:10.1055/s-0044-1788586.

    PMID: 39089672
  26. 26

    Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.

    Griffith SP, Wesselingh R, Seery N, et al.

    Journal of neurology 2024; (271(1)):310-324 doi:10.1007/s00415-023-11967-w.

    PMID: 37709946
  27. 27

    Subjective neuropsychological deficits in autoimmune encephalitis: Patient-informant discrepancies and cognitive test outcomes.

    Ko KY, Seery N, Kazzi C, et al.

    Journal of the neurological sciences 2025; (478()):123709 doi:10.1016/j.jns.2025.123709.

    PMID: 41075676
  28. 28

    Cognitive and Patient-Reported Outcome Measures in LGI-1-IgG Autoimmune Encephalitis.

    Ongphichetmetha T, Swetlik C, Thompson N, et al.

    Annals of clinical and translational neurology 2025; (12(8)):1670-1679 doi:10.1002/acn3.70105.

    PMID: 40542589

This page is for informational purposes only and does not constitute medical advice. It explains how to assess neurologic expertise, but your neurologist and care team must interpret symptoms, tests, and treatment decisions for your situation.